Incidence of West Nile virus infection in the Dallas-Fort Worth metropolitan area during the 2012 epidemic

Epidemiology and Infection

Volumn 145, Issue 12, 2017, Pages 2536-2544

  Williamson, P C ^a   Custer, B ^b   Biggerstaff, B J ^c   Lanciotti, R S ^c   Sayers, M H ^d,e   Eason, S J ^d   Dixon, M R ^a   Winkelman, V ^a   Lanteri, M C ^b   Petersen, L R ^c   Busch, M P ^b  

^a CREATIVE TESTING SOLUTIONS   (United States)

^b BLOOD SYSTEMS RESEARCH INSTITUTE   (United States)

^c NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^d Carter BloodCare   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Blood transfusion associated infections; incidence; West Nile virus

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDEMIC; ETHNIC DIFFERENCE; FEMALE; HEALTH CARE SURVEY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; POPULATION RESEARCH; POPULATION RISK; PUBLIC HEALTH; SEROCONVERSION; SEROLOGY; TEXAS; VIRUS VIRULENCE; WEST NILE FEVER; WEST NILE VIRUS; ADOLESCENT; BLOOD; BLOOD DONOR; METABOLISM; MIDDLE AGED; PHYSIOLOGY; SEROEPIDEMIOLOGY; STATISTICS AND NUMERICAL DATA; VERY ELDERLY; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, NEUTRALIZING; BLOOD DONORS; EPIDEMICS; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INCIDENCE; MALE; MIDDLE AGED; SEROEPIDEMIOLOGIC STUDIES; TEXAS; WEST NILE FEVER; WEST NILE VIRUS; YOUNG ADULT;

EID: 85028668508     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268816000042     Document Type: Article

References (25)

1. CDC. West Nile virus (http://www.cdc.gov/westnile/statsmaps/index.html).
2. Pybus OG, et al. Unifying the spatial epidemiology and molecular evolution of emerging epidemics. Proceedings of the National Academy of Sciences USA 2012; 109: 15066-15071.
3. Lindsey NP, et al. West Nile virus neuroinvasive disease incidence in the United States, 2002-2006. Vector Borne Zoonotic Diseases 2008; 8: 35-39.
4. Carson PJ, et al. Neuroinvasive disease and West Nile virus infection, North Dakota, USA, 1999-2008. Emerging Infectious Diseases 2012; 18: 684-686.
5. Petersen LR, et al. Estimated cumulative incidence of West Nile virus infection in US adults, 1999-2010. Epidemiology and Infection 2013; 141: 591-595.
6. Mostashari F, et al. Epidemic West Nile encephalitis, New York, 1999: results of a householdbased seroepidemiological survey. Lancet 2001; 358: 261-264.
7. Busch MP, et al. West Nile virus infections projected from blood donor screening data, United States, 2003. Emerging Infectious Diseases 2006; 12: 395-402.
8. Johnson AJ, et al. Detection of anti-arboviral immunoglobulin G by using a monoclonal antibody-based capture enzyme-linked immunosorbent assay. Journal of Clinical Microbiology 2000; 38: 1827-1831.
9. Martin DA, et al. Standardization of immunoglobulin M capture enzyme-linked immunosorbent assays for routine diagnosis of arboviral infections. Journal of Clinical Microbiology 2000; 38: 1823-1826.
10. Hogrefe WR, et al. Performance of immunoglobulin G (IgG) and IgM enzyme-linked immunosorbent assays using a West Nile virus recombinant antigen (preM/E) for detection of West Nile virus-and other flavivirusspecific antibodies. Journal of Clinical Microbiology 2004; 42: 4641-4648.
11. Tardei G, et al. Evaluation of immunoglobulin M (IgM) and IgG enzyme immunoassays in serologic diagnosis of West Nile Virus infection. Journal of Clinical Microbiology 2000; 38: 2232-2239.
12. Prince HE, et al. Development and persistence of West Nile virus-specific immunoglobulin M (IgM), IgA, and IgG in viremic blood donors. Journal of Clinical Microbiology 2005; 43: 4316-4320.
13. Busch MP, et al. Virus and antibody dynamics in acute west nile virus infection. Journal of Infectious Diseases 2008; 198: 984-993.
14. Lanteri MC, et al. West Nile virus nucleic acid persistence in whole blood months after clearance in plasma: implication for transfusion and transplantation safety. Transfusion 2014; 54: 3232-3241.
15. Heckman N, Lockhart R, Nielsen JD. Penalized regression, mixed effects models and appropriate modeling. Electronic Journal of Statistics 2013; 7: 35.
16. Durban M, et al. Simple fitting of subject-specific curves for longitudinal data. Statistics in Medicine 2005; 24: 1153-1167.
17. Ruppert D, Wand MP, Carroll RJ. Semiparimetric Regression. New York: Cambridge University Press, 2003.
18. Gart JJ, Nam J. Approximate interval estimation of the ratio of binomial parameters: a review and corrections for skewness. Biometrics 1988; 44: 323-338.
19. R: A language and environment for statistical computing. (http://www.R-project.org/).
20. Cervantes DT, et al. West Nile virus infection incidence based on donated blood samples and neuroinvasive disease reports, Northern Texas, USA, 2012. Emerging Infectious Diseases 2015; 21: 681-683.
21. Carson PJ, et al. Long-term clinical and neuropsychological outcomes of West Nile virus infection. Clinical Infectious Diseases 2006; 43: 723-730.
22. Anez G, et al. Evolutionary dynamics of West Nile virus in the United States, 1999-2011: phylogeny, selection pressure and evolutionary time-scale analysis. PLOS Neglected Tropical Diseases 2013; 7: e2245.
23. Mann BR, et al. Continued evolution of West Nile virus, Houston, Texas, USA, 2002-2012. Emerging Infectious Diseases 2013; 19: 1418-1427.
24. Mandalakas AM, et al.West Nile virus epidemic, northeast Ohio, 2002. Emerging Infectious Diseases 2005; 11: 1774-1777.
25. Zou S, et al. West Nile fever characteristics among viremic persons identified through blood donor screening. Journal of Infectious Diseases 2010; 202: 1354-1361.